Life Sci Turns 5


Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
Longevity Technology

Magnetic field tech captures the ‘song’ of a drug

The concept behind EMulate’s approach is mind-boggling. The company “records” the electromagnetic signature of specific molecules and is then able to use those recordings to effect changes in cellular behaviour, without using chemicals. In its most advanced programme, EMulate’s technology has completed feasibility clinical trials for adults and children with terminal brain cancer, using a recording derived from chemotherapy drug paclitaxel. We caught up with EMulate’s CEO Chris Rivera to find out more.

How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System

When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking:

Portage Biotech Creates A New Drug Development Model

“The Portage model has the same goal, which is to get to human proof-of-concept as quickly as possible,” says Walters. “


Pittsburgh Sees Transformation into Life Sciences Hotbed

“We’re in a steel mill town,” Keir Loiacono, chief executive officer at BlueSphere Bio told BioSpace. “I can look from my office out of the glass buildings and see coal barges going through, right next to young scientists in lab coats. It’s the old and the new – it’s everybody working together.”


Amidst Restructuring, Ambrx Doses First Patient with Anti-CD70 ADC

An anti-CD70 antibody-drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70, according to the company.


VIDEO: Tarpeyo reduces proteinuria, galactose-deficient IgA1 in IgA nephropathy

In this video from ASN Kidney Week, Jonathan Barratt, MBChB, PhD, discusses Calliditas Therapeutics’ Tarpeyo treatment, previously known as Nefecon, for patients with IgA nephropathy.

Process Development and Control for New Modalities

TFF Pharmaceuticals is advancing this technique as a platform technology for improving the formulation of complex modalities, including vaccines, small molecules and biologics, as dry powders. According to Hannon, this approach provides key advantages, including access to more convenient routes of administration due to aerosolization properties (i.e., inhalation or intranasal delivery) and elimination of the need for ultra-cold chain storage due to temperature stability.

College of Pharmacy Researchers Share Latest Findings on Novel Drug Delivery Technology

The Thin Film Freezing technology, invented by Dr. Williams and his team and advanced by Fort Worth-based TFF Pharmaceuticals, is developed via a well controlled process that involves rapid freezing and drying drugs into a powder.